US-based medical technology company Luminex has reported positive results from the evaluation of the ARIES System and Flu A/B and RSV CE-IVD Assay by the Department of Viroscience at Erasmus Medical Center in The Netherlands.
The Aries System is based on the universal assay protocol and extracts, amplifies and detects nucleic acid targets from multiple sample types and up to 12 different in vitro diagnostic (IVD) assays run together in random batches.
The higher throughput ARIES System provides two independent modules, each supporting one to six cassettes, allowing for both STAT and Batch testing of IVD and homebrew assays using MultiCode Reagents when using a universal assay protocol.
The ARIES Flu A/B and RSV Assay is used to detect and classify mainly three respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) by examining nasopharyngeal swabs (NPS) specimens from patients exhibiting signs of respiratory tract infection.
During the study, the ARIES platform and Flu A/B and RSV Assay demonstrated comparable high-clinical specificity and sensitivity and was proven superior to the established assays such as immunochromatographic tests and direct immunofluorescence assays.
The study also suggested the ease of usage of the systems compared to other rapid molecular test platforms.
Luminex EMEIA managing director Thomas Pracht said: "The Erasmus study demonstrates the quality and performance of the ARIES platform and the value of the system for molecular diagnostic labs that want to perform out of sync MDx testing in other words, outside of office hours testing or stat testing during office hours in between runs.
“The study also underlines the importance of point of impact tests, where results have an immediate impact on patient care and clinical decision making, even outside normal office hours."
Image: The ARIES Flu A/B and RSV Assay detects influenza virus. Photo: courtesy of Luminex Corporation.